Kuros Biosciences AG Stock Swiss Exchange
Equities
CH0011025217
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- CHF | - |
Apr. 24 | Kuros Biosciences Posts Higher Q1 Product Sales | MT |
Apr. 17 | Kuros Biosciences AG Approves Board of Director and Committee Changes | CI |
Sales 2022 | 17.99M 20.33M | Sales 2023 | 33.56M 37.94M | Capitalization | 128M 145M |
---|---|---|---|---|---|
Net income 2022 | -14M -15.82M | Net income 2023 | -13M -14.69M | EV / Sales 2022 | 1.76 x |
Net cash position 2022 | 22.08M 24.96M | Net cash position 2023 | 12M 13.56M | EV / Sales 2023 | 3.46 x |
P/E ratio 2022 |
-3.41
x | P/E ratio 2023 |
-9.18
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 64.98% |
Managers | Title | Age | Since |
---|---|---|---|
Joost de Bruijn
FOU | Founder | 58 | 17-12-03 |
Christopher Fair
CEO | Chief Executive Officer | 54 | 21-04-18 |
Daniel Geiger
DFI | Director of Finance/CFO | - | 23-02-16 |
Members of the board | Title | Age | Since |
---|---|---|---|
Christopher Fair
CEO | Chief Executive Officer | 54 | 21-04-18 |
Joost de Bruijn
FOU | Founder | 58 | 17-12-03 |
Chairman | 67 | 17-05-22 |
1st Jan change | Capi. | |
---|---|---|
+20.03% | 126B | |
+23.61% | 117B | |
+23.26% | 27.52B | |
-18.07% | 20.87B | |
-15.13% | 17.01B | |
-14.81% | 16.26B | |
+9.78% | 14.56B | |
-46.10% | 15.09B | |
+52.34% | 13.89B |